UNSPSC 51422211: Triamcinolone acetonide hemisuccinate

This classification denotes a therapeutic glucocorticoid with the molecular formula C28H35FO9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Z83R2HM9L, chemically known as pregna-1,4-diene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11.beta.,16.alpha.)-, but more generally known as triamcinolone acetonide hemisuccinate, which bears US NIH Compound Identifier 3032435.

European Medicines Agency schedules triamcinolone acetonide hemisuccinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11251MIG. Most nations, for tariff purposes, schedule triamcinolone acetonide hemisuccinate under HS 29372200. SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COC(=O)CCC(=O)O)CCC5=CC(=O)C=C[C@@]53C)F)O.

UNSPSC 51422211 Triamcinolone acetonide hemisuccinate, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The code nominally covers a specific corticosteroid pharmaceutical ingredient, yet the only two recent opportunities in the dataset are for naloxone and drug deactivation systems (Seminole County, Florida) and a Texas HHS information-gathering initiative on direct-to-manufacturer prescription programs—neither of which involves triamcinolone acetonide hemisuccinate or any corticosteroid product. The mismatch suggests either a tagging error in the sourced opportunities or minimal actual procurement under the code's stated pharmaceutical scope in state and local markets during the review period.

The two opportunities present show no meaningful pattern. Seminole County issued an IFB (Solicitation Number IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems, but that solicitation predates the current date by nearly three years and addresses emergency response supplies unrelated to corticosteroids. The Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription contracting models, but it does not specify therapeutic categories or identify triamcinolone as a target product. No other state or local opportunities for triamcinolone acetonide hemisuccinate or corticosteroid pharmaceuticals appear in the recent record. State and local procurement under this code shows no discernible recent activity in the actual scope the code nominally covers.